REVB צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Revelation Bio

The quarterly EPS percentage change reflects the profit dynamics of Revelation Biosciences (REVB), where 88.30 captures the value of this parameter. The company is currently undergoing a phase of intensive scientific research characterized by high biological risks. Growth potential is based on the unique Gemini drug for kidney protection, while further success depends on securing financing and the test results of allergy treatments.

The pricing power of Revelation Biosciences (REVB) within the inelastic demand segment for the Gemini drug is reflected in the quarterly growth dynamics of earnings per share. This indicator measures the percentage change in net income per common share over a quarter, allowing for an assessment of the actual efficiency of business capitalization; however, a final conclusion requires comparing this growth rate with the issuer's debt load.